FMED vs. CNCR

Last updated Jun 24, 2026

FMED (Fidelity Disruptive Medicine ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds. FMED is actively managed, while CNCR is passively managed. FMED charges 0.50%/yr vs 0.79%/yr for CNCR.

Performance

FMED vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fidelity Disruptive Medicine ETF (FMED) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

FMED

• 1D: 1.03%
• 1M: 6.62%
• YTD: -2.44%
• 6M: -4.06%
• 1Y: 12.97%
• 3Y*: 1.97%
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

FMED vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
FMED Fidelity Disruptive Medicine ETF	3.94%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

FMED vs. CNCR - Sectors Allocation Comparison

Sectors	FMED	CNCR
Healthcare	97.6%	96.6%
Technology	0.9%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

FMED vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FMED

FMED Risk / Return Rank: 19
FMED Sharpe Ratio Rank: 21
FMED Sortino Ratio Rank: 21
FMED Omega Ratio Rank: 19
FMED Calmar Ratio Rank: 17
FMED Martin Ratio Rank: 16

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FMED vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fidelity Disruptive Medicine ETF (FMED) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	FMED	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	0.68	—	—
Sortino ratio: Return per unit of downside risk	1.12	—	—
Omega ratio: Gain probability vs. loss probability	1.13	—	—
Calmar ratio: Return relative to maximum drawdown	0.71	—	—
Martin ratio: Return relative to average drawdown	1.55	—	—

Drawdowns

FMED vs. CNCR - Drawdown Comparison

The maximum FMED drawdown since its inception was -21.84%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for FMED and CNCR.

Drawdown Indicators

	FMED	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-21.84%	0.00%	-21.84%
Max Drawdown (1Y) Largest decline over 1 year	-18.33%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-21.84%	—	—
Current Drawdown Current decline from peak	-8.48%	0.00%	-8.48%
Average Drawdown Average peak-to-trough decline	-7.11%	0.00%	-7.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.38%	—	—

Volatility

Volatility by Period

	FMED	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.57%	—	—
Volatility (6M) Calculated over the trailing 6-month period	15.04%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	19.27%	0.00%	+19.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.53%	0.00%	+18.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.53%	0.00%	+18.53%

FMED vs. CNCR - Expense Ratio Comparison

FMED has a 0.50% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

FMED vs. CNCR - Dividend Comparison

Neither FMED nor CNCR has paid dividends to shareholders.

Position	TTM	2025	2024
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%
FMED Fidelity Disruptive Medicine ETF	0.00%	0.00%	0.46%

Frequently Asked Questions

Which ETF is better, FMED or CNCR?

On fees, FMED is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, FMED or CNCR?

FMED is cheaper with a 0.50% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, FMED or CNCR?

FMED and CNCR have nearly identical dividend yields, around 0.00%.

What is the main difference between FMED and CNCR?

They also come from different issuers: Fidelity and Exchange Traded Concepts. Their fees differ too: 0.50% for FMED and 0.79% for CNCR.